RMD Stock Recent News

Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

ResMed (RMD) came out with quarterly earnings of $2.37 per share, beating the Zacks Consensus Estimate of $2.36 per share. This compares to earnings of $2.13 per share a year ago.

Resmed beat Wall Street estimates for third-quarter profit on Wednesday, driven by demand for its sleep apnea devices used to manage the common sleep disorder.

Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at  http://investor.resmed.com

Former Illumina, MSCI, and Moody's executive brings extensive experience leading engagement with the global investment community Former Illumina, MSCI, and Moody's executive brings extensive experience leading engagement with the global investment community

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for ResMed (RMD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.

ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

ResMed (RMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Resmed launches NightOwl, an FDA-cleared home sleep apnea test, in the United States to diagnose OSA at home.